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dual-energy X-ray absorptiometry), comprehensive echocardiography, and blood testing. Subjects were followed up
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display cachexia (19%). The extent of RV dysfunction correlated with greater antecedent weight loss and a lower fat/
lean body mass ratio. Over a median follow-up of 541 days, there were 150 events (37%). Risk of event was greater
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associated with a lower event rate (HR per kg/m2: 0.92 [95% CI: 0.88 to 0.96]), and this protection was mediated by
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interrelated. Wasting of fat but not of lean mass was predictive of adverse outcome, suggesting that fat loss is either
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1661Previous studies examining determinants of HF-related
cachexia have reported no relationship to left ventricular
(LV) impairment, but, importantly, relationships with right
ventricular (RV) function were not examined (15–17). Right
ventricular dysfunction (RVD) is associated with worse
outcome in HF (18) independent of the degree of pulmonary
hypertension (19). Increased right heart ﬁlling pressure and
tricuspid regurgitation have been linked to body fat depletion
(10,20) and low body mass index (BMI) (7), but RV function
itself was not quantiﬁed in these studies. By maintaining
forward cardiac output and protecting splanchnic organs from
passive venous hypertension (21), the right ventricle may play
a critical role in delaying the onset of wasting in HF.
Accordingly, we investigated the relationships between
RV function, body composition, and prognosis in a prospec-
tively deﬁned group of patients with advanced HF. We
hypothesized that preserved RV function is protective
against cardiac cachexia and that RVD is linked to accel-
erated weight loss, abnormal body composition, and wors-
ened prognosis in advanced HF.
Methods
The study enrolled patients with chronic (>6 months)
advanced systolic HF (ejection fraction <50%) electively
hospitalized at a non–intensive care unit ward at The
Institute for Clinical and Experimental Medicine in Prague
between November 2007 and August 2011 for consideration
of advanced therapies. Two cardiologists (V.M., M.K.)
identiﬁed potential participants from the list of planned
procedures; study coordinators then reviewed exclusion
eligibility criteria and obtained written consent. Patients
with acute HF decompensation, hemodynamic instability or
reversible cardiac dysfunction (e.g., planned valve surgery,
revascularization, tachycardia-induced cardiomyopathy), active
malignancy, chronic infection, history of intentional weight
loss attempts in the past year, or those unwilling to participate
were excluded. The study was approved by the ethical
committee of the Institute of Clinical and Experimental
Medicine.
All subjects underwent morning fasting blood sampling for
laboratory analysis and completed a medical history, Minne-
sota Living with Heart Failure questionnaire, and an an-
thropometric and echocardiography examination (Vivid7,
General Electric Healthcare, Wauwatosa, Wisconsin). LV
function and dimensions were measured according to
contemporary recommendations by a physician with an
expertise in echocardiography (22). Mitral and tricuspid
regurgitations were assessed semiquantitatively and expressed
in 3 grades (absent, insigniﬁcant, and signiﬁcant). RV systolic
pressure was estimated from the tricuspid regurgitation velocity
(available in 75%) and right atrial pressure estimate, based on
inferior vena cava diameter (22). RVD was quantiﬁed (0 to 3)
in an apical 4-chamber view by using tricuspid annular systolic
excursion (M-mode TAPSE) (23) and tissue systolic velocity
(Sm) (24) with the following cutoffs: RVD0, normal:TAPSE >20 mm, Sm >12 cm/s;
RVD1,mild impairment:TAPSE
16 to 20 mm, Sm 9 to 12 cm/s;
RVD2, moderate: TAPSE 10 to
15 mm, Sm 6 to 8 cm/s; and
RVD3, severe: TAPSE<10 mm,
Sm <6 cm/s. In case of disagree-
ment of criteria, qualitative visual
estimation of RV motion in apical
4-chamber was also taken into
account. Because RVD2-3 and
RVD0-1 grades had similar prog-
nostic impact, they were aggre-
gated for dichotomized analyses.
Body weight was measured by
using an electronic scale (HBF-
510W, Omron, Japan). Antecedent weight 6 months before
the evaluation was carefully ascertained by subjects’ historical
recollection and by review of available medical records, as
done previously (9,12,15). Four-site skinfold thickness
(triplicate measurement in nondominant subscapular, bicip-
ital, tricipital, and suprailiac areas) was measured by using
Best’s caliper with controlled grip strength. In 19 subjects,
between-day reproducibility of skinfold measurement was
excellent (r2 > 0.9) (Online Fig. 1A). Skinfold sum was
converted into total body fat by using established age- and
sex-speciﬁc formulas (25), and fat mass index or fat-free mass
index was obtained by indexing to square of body height (26).
Mathematically, the sum of the fat mass index and the fat-free
mass index then corresponds to BMI (26). In the last one-
third of subjects enrolled in the study (n ¼ 162), body
composition was also measured by using dual-energy X-ray
densitometry (DEXA) (Lunar prodigy, General Electric
Healthcare) to externally validate results. Body fat proportion
according to DEXA and the skinfold method showed good
agreement (r2¼ 0.56) (Online Fig. 1B). Cardiac cachexia was
deﬁned by the presence of signiﬁcant weight loss (>5%
within 6 months), as done previously in landmark studies that
deﬁned prognostic impact of weight loss (cachexia) in HF
(8,9) and by simultaneous presence of abnormal biochemistry
(C-reactive protein >5 mg/l or hemoglobin <120 g/l or
albumin <32 g/l) as recently recommended to enhance
speciﬁcity (27).
Glomerular ﬁltration rate was estimated by using the
Modiﬁcation of Diet in the Renal Disease equation (28).
Plasma sodium, albumin, aspartate-aminotransferase, glu-
cose, creatinine, and cholesterol were measured by using an
automated Abbott Architect ci1600 analyzer. The B-type
natriuretic peptide (BNP) concentrations were measured
by using microparticle immunoassay (Architect BNP,
Abbott Laboratories, Chicago, Illinois; long-term an-
alytical CV 4.5%). Adiponectin was measured using
high-sensitivity enzyme-linked immunoadsorbent assay
(BioVendor, Brno, Czech Republic; CV 6.2%), leptin by
using radioimmunoassay (Millipore, Billerica, Massachu-
setts; CV 4.7%), and cortisol by using radioimmunoassay
Table 1 Clinical, Echocardiography, and Anthropometric Parameters
All
(n ¼ 408)
No RVD
(n ¼ 198)
RVD
(n ¼ 210) p Value
No Cachexia
(n ¼ 330)
Cachexia
(n ¼ 78) p Value
Age (yrs) 59  11 59  11 59  11 0.46 59  11 60  11 0.35
Male (%) 84 80 89 0.014 83 90 0.35
Ischemic etiology (%) 53 52 55 0.45 52 58 0.40
NYHA functional class (I to IV) 2.8  0.6 2.7  0.5 2.9  0.6 0.0001 2.8  0.6 2.9  0.5 0.04
MLHFQ sum 47  22 43  22 51  22 0.002 45  21 55  24 0.003
Anorexia grade (1–5) 1.9  1.6 1.6  1.6 2.1  1.6 0.001 1.7  1.5 2.5  1.8 0.001
RV lead/deﬁbrillator (%) 75/66 76/65 75/67 0.90/0.66 75/65 78/69 0.53/0.46
Diabetes mellitus (%) 34 30 38 0.07 33 37 0.52
Systolic/diastolic BP (mm Hg) 115  19/72  11 119  20/75  11 111  17/70  11 <0.0001/0.0001 116  19/72  12 110  18/69  9 0.03/0.0003
Heart rate (beats/min) 77  15 74  14 80  15 <0.0001 76  15 82  15 0.005
Edema present (%) 25 18 31 0.001 23 31 0.18
Furosemide daily dose (mg) 92  82 82  73 111  88 0.0006 95  82 108  83 0.24
BB/ACEI or ARB/ARA use (%) 92/85/77 92/88/74 92/82/80 0.9/0.06/0.06 94/89/75 83/68/87 0.04/<0.001/0.01
Echocardiography
LV ejection fraction (%) 25  6 27  7 23  5 <0.0001 26  6.7 24  5.3 0.09
LV end-diastolic diameter (mm) 70  9 69  9 71  8 0.04 70  9 70  8 0.62
Mitral regurgitation grade (0–2) 0.9  0.8 0.7  0.8 1.1  0.8 0.0001 0.9  0.8 0.9  0.8 0.48
RV diameter (mm) 30  6 28  6 32  6 <0.0001 30  6.5 32  5.6 0.006
RVD grade (0–3) 1.4  1.0 0.6  0.5 2.3  0.4 <0.0001 1.4  1.7 1.7  0.9 0.003
Tricuspid regurgitation grade (0–2) 0.5  0.7 0.2  0.5 0.7  0.8 <0.0001 0.5  0.7 0.6  0.7 0.22
Inferior vena cava diameter (mm) 20  6 18  5 22  6 <0.0001 20  5.9 21  6.6 0.11
Tricuspid regurgitation gradient (mm Hg) 36  12 34  11 38  12 0.016 37  12 35  12 0.19
RVSP estimate (mm Hg) 46  12 43  11 48  12 0.001 46  12 45  12 0.32
Anthropometrics
Body mass index (kg/m2) 27.8  4.8 28.6  4.5 27.1  4.8 0.002 28.3  4.6 25.6  4.3 <0.0001
Fat mass index (kg/m2) 7.2  3.8 7.8  3.6 6.7  3.9 0.005 7.6  3.8 5.6  3.2 <0.0001
Fat-free mass index (kg/m2) 20.6  3.0 20.7  3.1 20.3  2.9 0.21 20.7  3.1 20.0  2.5 0.05
Waist circumference (cm) 102  13 103  11 100  14 0.02 102  13 98  12 0.008
DEXA fat mass (kg) 28  11 30  11 25  10 0.002 29  10 24  11 0.02
Lean mass (kg) 54  9.6 55  10 54  9 0.64 55  9.8 52  8.6 0.09
Body weight loss in 6 months (kg) 2.8  9 1.4  8 4.0  10 0.002 0.2  7.2 13  8 <0.0001
Body weight loss >5% in 6 months (%) 33 27 39 0.01 17 100 <0.0001
Cachexia (%) 19 14 24 0.01 0 100 <0.0001
Values are mean  SD or %. Fat-free mass index was derived from skinfold measurements performed in all subjects.
ACEI ¼ angiotensin-converting enzyme antagonist; ARA ¼ aldosterone receptor antagonist; ARB ¼ angiotensin receptor blocker; BB ¼ beta-blocker; BP ¼ blood pressure; CAD ¼ coronary artery disease; DEXA ¼ dual-energy X-ray absorptiometry (n ¼ 162); LV ¼ left
ventricular; MLHFQ ¼ Minnesota Living with Heart Failure questionnaire; No RVD ¼ RVD grades 0–1; NYHA ¼ New York Heart Association; RV ¼ right ventricular; RVD ¼ right ventricular dysfunction; RVD present ¼ RVD grades 2–3; RVSP ¼ right ventricular systolic pressure
estimate (n ¼ 306)
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Table 2 Right Heart Catheterization and Laboratory Parameters
All
(N ¼ 408)
No RVD
(n ¼ 198)
RVD
(n ¼ 210) p Value
No Cachexia
(n ¼ 330)
Cachexia
(n ¼ 78) p Value
Right heart catheterization
Right atrium (mm Hg) 9.3  6 8.1  6 10  6 0.01 9.3  6.2 9.4  5.7 0.92
PA mean (mm Hg) 34  12 34  12 36  11 0.008 34  12 35  9 0.68
PA wedge pressure (mm Hg) 23  9 22  10 25  8 0.02 23  9 25  7 0.25
Cardiac output (l/min) 4.0  1.0 4.2  0.9 3.9  1.0 0.03 4.0  0.9 4.0  1.2 0.82
Biochemistry
GFR (ml/min/1.73 m2) 52  18 54  19 50  17 0.20 53  19 46  14 0.0004
Hemoglobin (g/dl) 13.9  1.7 13.9  1.7 14.0  1.7 0.04 14.1  1.6 13.5  2.0 0.04
C-reactive protein (mg/l) 8.3  16 6.8  12 9.8  18 0.05 6.8  13 15  24 0.004
Alanine aminotransferase (mkat/l) 0.8  0.9 0.8  0.9 0.7  1.0 0.7 0.8  0.8 0.8  1.1 0.63
Total protein (g/l) 70  6.4 69  6 70  7 0.03 69  6.3 70  7 0.42
Albumin (g/l) 38  4 38  4 38  4 0.76 39  4 36  5 <0.0001
Total cholesterol (mmol/l) 4.2  1.1 4.4  1.0 4.1  1.1 0.002 4.3  1.1 4.0  0.9 0.03
Glucose (mmol/l) 6.3  2.4 6.0  2.0 6.5  2.8 0.10 6.3  2.5 6.2  2.2 0.96
Hormones
BNP (pg/l) 861  822 612  648 1094  897 <0.0001 746  723 1349  1019 <0.0001
Cortisol (nmol/l) 513  173 490  170 535  173 0.012 506  169 544  186 0.06
Leptin (mg/l) 18  15 20  15 16  14 0.006 19  15 14  12 0.007
Adiponectin (mg/l) 37  31 30  23 43  36 <0.0001 33  28 53  38 <0.0001
Values are mean  SD. Right heart catheterization was available in 193 subjects.
BNP ¼ B-type natriuretic peptide; GFR ¼ glomerular ﬁltration rate; PA ¼ pulmonary artery; other abbreviations as in Table 1.
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1663(Beckman-Coulter, Prague, Czech Republic; CV 9.2%).
Right heart catheterization was performed via jugular access
using a balloon-tipped thermodilution catheter (Corodyn,
Braun, Melsungen, Germany) and a standard data acquisition
system (MacLab, General Electric Healthcare).
Adverse outcomes were deﬁned by the combined endpoint
of death without transplantation, urgent heart transplantation,
or implantation of ventricular assist device. Because time to
nonurgent transplantation reﬂects donor availability rather
than recipient’s condition, those patients were censored as
having no outcome at the day of transplantation. Data were
analyzed by using JMP10 software (SAS Institute, Inc., Cary,
North Carolina). Differences between groups were tested by
using the chi-square test, unpaired Student t test, or analysis
of variance. Logistic regression analysis was used to identify
the predictors of cachexia. The impact on survival was tested
by using the Cox proportional hazards model.
Results
A total of 408 predominantly male subjects with chronic HF
(median duration 6.3 years; interquartile range 2.4 to 12 years)
were enrolled (Table 1). Optimal medical and device therapies
(45% cardiac resynchronization therapy, 66% implantable
cardioverter-deﬁbrillator) were widely used. Subjects displayed
signiﬁcant LV remodeling and dysfunction. Pulmonary hy-
pertension (estimated RV systolic pressure >35 mm Hg) was
present in 79%.Right heart catheterization (n¼ 193) (Table 2)
revealed increased pulmonary artery (PA) and LV ﬁlling
pressures, but RA pressures and cardiac output were relatively
preserved, consistent with a reasonably compensated state (on
average). Moderate or severe RVD was present in 51% ofsubjects. Only 2% of subjects had BMI 20 kg/m2, and most
(70%) were either overweight or obese. About one-half (49%)
reported unintended weight loss in the past 6 months and 33%
had weight loss of >5% of body weight. Cachexia, deﬁned by
weight loss and laboratory criteria, was present in 19% of
subjects.
Association of RVD and cachexia. Patients with RVD
had more severe HF symptoms, lower systemic blood
pressures and cardiac output, more tricuspid regurgitation,
and greater pressure load imposed on the right ventricle
(Tables 1 and 2). Patients with RV dysfunction were leaner,
had more pronounced weight loss, more often fulﬁlled
cachexia criteria, and had lower body mass and less body fat
mass than those with preserved RV function, in contrast to
lean mass that was similar in both groups (Fig. 1, Table 1).
In the whole cohort, there was a stepwise relation between
RVD grade, weight loss, and ratio of fat mass to lean mass
by DEXA (Fig. 2). Weight change and body composition
also signiﬁcantly (both p < 0.001) inversely correlated with
the ratio of RV to LV function, indicating a relatively
stronger link of cachexia to compromised right heart,
compared with left heart impairment.
When patients were dichotomized according to the pres-
ence of cachexia, cachectic subjects displayed greater RV
dilation and more severe RVD, while prevalence of tricuspid
regurgitation, pulmonary hypertension, and right atrial pres-
sures were similar in noncachectic subjects (Tables 1 and 2).
Among the cardiac indexes, onlyRVcharacteristics, but notLV
dimension or ejection fraction, discriminated betweencachectic
versus noncachetic patients. Cachectic patients had a lower
quality of life, more anorexia, and higher heart rate; lower
systemic blood pressure; lower use of angiotensin-converting
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Figure 1 Body Composition by DEXA
Impact of signiﬁcant right ventricular dysfunction (RVD) (moderate and severe
grade) or cachexia on fat and lean mass, determined by dual-energy X-ray
absorptiometry (DEXA). Values were adjusted to body height. Lines and brackets
represent mean  SD.
Melenovsky et al. JACC Vol. 62, No. 18, 2013
RV Dysfunction and Cachexia in Advanced Heart Failure October 29, 2013:1660–70
1664enzyme inhibitors/angiotensin receptor blockers and beta-
blockers; and more renal dysfunction, anemia, and inﬂamma-
tory/stress response activation. In contrast, HF etiology and
duration, hemodynamics, liver function, presence of edema,
and impaired glucose tolerance were similar in cachectic and
noncachectic groups.
Cachectic subjects demonstrated w2-fold higher BNP
(despite similar hemodynamics), lower leptin levels, and
markedly higher adiponectin levels. Adiponectin but not
leptin remained signiﬁcantly different when adjusted to
percentage of body fat (p ¼ 0.018). Skinfold-derived body
composition analysis showed that the BMI difference
between cachectic and noncachectic subjects was attributable
mainly to low-fat mass, although fat-free mass was only
marginally reduced (Table 1). The reduction in fat mass but
preserved lean mass in cachectic patients was conﬁrmed by
DEXA (n ¼ 162) (Fig. 1).
Logistic regression was used to delineate which cardiac,
clinical, and humoral factors were independently associated
with cachexia (Table 3). Among the cardiac parameters, only
RVD remained signiﬁcant in the multivariate model topredict cachexia. Notably, tricuspid regurgitation grade and
velocity, inferior vena cava diameter, LV dimension, or
ejection fraction and all other echocardiographic indexes
were not predictive of cardiac cachexia in multivariate
analysis. Among clinical factors, the absence of angiotensin-
converting enzyme inhibitors/angiotensin receptor blockers
or beta-blockers remained independently associated with
cachexia. Among humoral factors, adiponectin and BNP
showed strong independent relationships to cachexia.
The inﬂuence of cachexia and RVD on prognosis. After
a median follow-up of 541 days (interquartile range: 254 to
873 days), 150 (37%) of 408 patients had an adverse event.
The presence of RVdysfunction (hazard ratio [HR]: 3.13;
95% conﬁdence interval (CI): 2.09 to 4.79; p < 0.0001) or
cachexia (HR: 3.56; 95% CI: 1.65 to 7.00; p ¼ 0.0002) was
strongly associated with adverse events, and risk was much
greater if both cachexia and RVD were present (HR: 6.67;
95% CI: 4.08 to 10.9; p < 0.0001 vs. noncachectic patients
with normal RV) (Fig. 3). In univariate Cox analysis,
antecedent weight loss (>5% in past 6 months) was asso-
ciated with increased events (HR: 1.85; 95% CI: 1.32 to
2.59; p ¼ 0.0005) (Online Fig. 2). When the lean and fat
components of BMI were separated according to skinfold-
derived body composition, the protective effect of BMI on
adverse outcomes (HR per kg/m2: 0.92 [95% CI: 0.88 to
0.96]; p < 0.001) (Fig. 4A) was conferred by fat mass index
(HR per kg/m2: 0.91 [95% CI: 0.87 to 0.96]; p < 0.001)
rather than fat-free mass index (HR per kg/m2: 0.97 [95%
CI: 0.92 to 1.03]; p ¼ 0.40). Although fat-free mass dis-
played a ﬂat relationship with events, fat mass demonstrated
a steep, almost linear inverse relationship to the event risk
(Fig. 4B). Multivariate Cox analysis (Table 4) incorporating
all signiﬁcant predictors showed that both RVD and
cachexia, in addition to pulmonary hypertension, age, heart
rate, and absence of neurohumoral inhibition, were inde-
pendent predictors of event-free survival.
Discussion
The study shows that involuntary weight loss in advanced
HF, the deﬁning feature of cardiac cachexia, is indepen-
dently associated with impaired RV function. Circulating
BNP, adiponectin, absence of neurohormonal antagonist
therapy, and RVD were the only independent predictors of
cachexia. Body composition analysis in patients with RV
dysfunction demonstrated more pronounced depletion of
body fat than of lean mass. In support of their mutual
interrelation, both RVD and cachexia displayed an additive
adverse impact on prognosis. Higher body mass was asso-
ciated with a better prognosis in keeping with previous
studies documenting the obesity paradox, but interestingly,
it was the amount of fat rather than lean mass that predicted
better outcome. This ﬁnding is somewhat at odds with
current pathophysiological models that emphasize prefer-
ential maintenance of lean mass to prevent cachexia and
adverse outcomes (29).
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1665The association between RVD and cachexia has not
received attention because previous studies examining the
prognostic role of RV function in HF did not report
anthropometric data (19,30,31), and, conversely, studies of
cardiac cachexia have provided no details regarding RV
function (3,4,8,9,15). Two small (10,20) and one larger (7)
study found that cachexia was associated with increased right
atrial pressure (10) or tricuspid regurgitation (7,10,20),
pointing toward the role of right heart impairment; however,
in these studies, RV function was not assessed. Despite the
fact that patients with RV dysfunction also have more left
heart dysfunction due to shared myocardial disease (32), our
data indicate that cachexia is linked more speciﬁcally to right
than left heart impairment (Fig. 2).
Impaired RV function can promote weight loss and
cachexia by several potential pathways. RV dysfunction
leads to systemic venous congestion in the hepatic and
splanchnic beds, which may be associated with anorexia,
intestinal dysmotility, fat malabsorption (33), and increased
intestinal permeability (13), with ensuing protein loss (34)and endotoxin translocation (35). Despite that our patients
had relatively low ﬁlling pressure at the time of examination,
it is likely that during periods of decompensation, venous
congestion would have been more dramatic, potentially
contributing to promotion of cachexia. RV dysfunction also
contributes to reduced forward cardiac output that begets
neurohormonal activation and pro-catabolic effects. Higher
cortisol, lower cardiac output, and increased BNP found in
patients with RVD endorse these mechanisms. The likely
contribution of natriuretic peptide–related metabolic effects
is supported by the fact that BNP emerged as one of the
strongest predictors of cachexia in our study. Previously, we
have demonstrated that bioactive BNP is able to strongly
stimulate lipolysis of adipose tissue in patients with HF (36).
Natriuretic peptides can also act indirectly by inducing
secretion of adiponectin that promotes substrate utilization
(37), weight loss, and, perhaps, HF mortality (38).
In multivariate regression analysis, RVD predicted
cachexia even after adjusting for tricuspid regurgitation,
estimated right atrial pressure and PA pressure, emphasizing
Table 3 Logistic Regression Analysis of Hormonal, Cardiac, and Clinical Factors Associated With Cachexia in All HF Subjects (n ¼ 408)
Univariate Multivariate
HR 95% CI Chi-Square p Value HR 95% CI Chi-Square p Value
Hormones All model 36.4
BNP (pg/l) 1.0007 0.99–1.001 28.2 <0.0001 1.0006 1.0002–1.0009 10.9 0.0009
Cortisol (nmol/l) 1.001 0.99–1.003 2.6 0.10 1.0008 0.99–1.01 0.9 0.35
Leptin (mg/l) 0.97 0.95–0.99 5.4 0.02 0.98 0.95–1.01 1.8 0.18
Adiponectin (mg/l) 1.02 1.010–1.023 19.6 <0.0001 1.009 1.0001–1.019 4.0 0.047
Cardiac characteristics All model 13.1
RV diameter (mm) 1.04 1.01–1.08 5.9 0.015 1.008 0.95–1.06 0.1 0.77
LV end-diastolic diameter (mm) 0.99 0.97–1.02 0.2 0.63 0.98 0.94–1.01 1.5 0.22
LV ejection fraction (mm) 0.97 0.92–1.01 2.3 0.13 0.97 0.92–1.03 0.9 0.36
Tricuspid regurgitation gradient (mm Hg) 0.98 0.96–1.01 1.8 0.18 0.98 0.96–1.01 1.8 0.18
Inferior vena cava diameter (mm) 1.03 0.99–1.08 2.8 0.09 1.02 0.96–1.08 0.4 0.54
RVD grade (0–3) 1.48 1.14–1.94 8.7 0.003 1.52 1.07–2.20 5.1 0.020
Tricuspid regurgitation grade (0–2) 1.53 0.77–3.0 0.2 0.21 0.81 0.50–1.28 0.8 0.37
Mitral regurgitation grade (0–2) 1.10 0.82–1.5 0.5 0.50 0.95 0.63–1.43 0.1 0.81
Clinical variables All model 40.3
Age (yrs) 1.01 0.98–1.03 0.8 0.36 1.02 0.95–1.01 1.4 0.24
HF duration (yrs) 0.98 0.95–1.03 0.3 0.56 d d d d
NYHA functional class (I to IV) 1.56 0.99–2.48 3.7 0.05 1.13 0.53–1.47 0.2 0.63
Diabetes mellitus, present 1.18 0.70–1.97 0.4 0.52 d d d d
ACEI/ARB therapy, present 0.26 0.14–0.47 18.9 <0.001 0.29 0.15–0.55 14.1 0.0002
BB therapy, present 0.30 0.14–0.66 8.7 0.003 0.35 0.16–0.80 6.0 0.014
Systolic blood pressure (mm Hg) 0.98 0.97–1.03 5.0 0.026 1.01 0.99–1.02 2.0 0.16
Heart rate (beats/min) 1.02 1.01–1.03 7.9 0.005 0.98 0.97–1.01 2.8 0.09
GFR (ml/min/1.73 m) 0.98 0.96–0.99 9.9 0.002 1.01 0.99–1.03 1.7 0.20
Ischemic HF etiology 0.80 0.49–1.33 0.7 0.40 d d d d
Male 1.8 0.86–4.21 2.3 0.13 1.09 0.48–2.73 0.04 0.84
HF ¼ heart failure; HR ¼ hazard ratio; other abbreviations as in Tables 1 and 2.
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Figure 3 RV Dysfunction, Cachexia, and Survival
Kaplan-Meier plots displaying the effect of (A) RVD grade, (B) presence of cachexia, or (C) both on freedom of adverse event (combined endpoint of death without heart
transplantation, urgent transplantation or assist device implantation). In C, RVD integrated moderate and severe grade. Cachexia was deﬁned by history of>5% body weight loss
in past 6 months and abnormal laboratory ﬁndings (see the Methods section). Abbreviation as in Figure 1.
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1667the role of RV functional response to pressure overload
(21,39), rather than the degree of pressure overload itself.
Persistent RV impairment may be a consequence of load/
perfusion mismatch or it may integrate transient episodes of
overloading that can occur during exercise or of hyper-
volemia (21). Conversely, causal links between cachexia and
RVD may be bidirectional in nature; that is, cytokines and
metabolites released during wasting may adversely inﬂuence
cardiac performance (Fig. 5) (40). Tumor necrosis factor–
alpha, a cytokine elevated in cardiac cachexia (41), has
potent negative inotropic effects (42) and is correlated with0.9 1.0 1.1
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Figure 4 Body Composition and Outcome in HF
The effect of body mass index (BMI) and its components (BMI ¼ fat mass index [FMI] þ
thickness (26) on risk of adverse outcome (death without transplantation, urgent transplan
ratios (and 95% conﬁdence interval) for the whole population, (B) risk ratios (dots þ solid
degree polynomial ﬁt.RV ejection fraction, but not LV ejection fraction, in
patients with biventricular HF (43). Future studies should
examine whether improvement in RV function may alleviate
cardiac cachexia or vice versa. Indeed, recent studies have
reported that the phosphodiesterase 5 inhibitor sildenaﬁl
enhances RV function (44) and may attenuate weight loss in
advanced HF (45).
Subjects with cardiac cachexia in this study were notably
in the upper range of normal BMI. Normal body habitus
does not exclude ongoing wasting, particularly in previously
obese HF subjects. The relatively larger depletion of fat inI
30 35
m
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fat-free mass index [FFMI]) derived from anthropometric measurements of skinfold
t or assist device implantation) in univariate Cox proportional hazards model. (A) Risk
line) and 95% conﬁdence interval (interrupted line) per integers of variables; second
Table 4 Predictors of Adverse Outcome by Cox Proportional Hazards Analysis in All HF Subjects (N ¼ 408)
Univariate
Multivariate
(Chi-Square ¼ 92, p < 0.001)
HR 95% CI Chi-Square p Value HR 95% CI Chi-Square p Value
Natremia (mmol/l) 0.90 0.86–0.94 22 <0.0001 0.96 0.91–1.02 1.9 0.16
Age (yrs) 0.98 0.96–0.99 6.8 0.009 0.97 0.95–0.99 7.2 0.007
Male 2.37 1.35–4.66 9.7 0.002 1.13 0.57–2.33 0.1 0.73
NYHA functional class (I to IV) 1.77 1.31–2.40 14 0.002 1.26 0.86–1.83 1.4 0.24
Systolic blood pressure (mm Hg) 0.98 0.97–0.99 26 <0.0001 0.99 0.98–0.99 4.4 0.036
Heart rate (beats/min) 1.01 1.004–1.02 6.9 0.009 0.99 0.98–1.01 1.0 0.32
Inferior vena cava diameter (mm) 1.05 1.03–1.08 16 <0.0001 0.97 0.94–1.01 2.0 0.16
RVD present 3.09 2.18–4.45 43 <0.0001 2.00 1.24–3.33 8.3 0.003
Tricuspid regurgitation gradient (mm Hg) 1.02 1.01–1.03 6.7 0.010 1.02 1.006–1.04 7.5 0.006
ACEI or ARB use, present 0.37 0.25–0.55 21 <0.0001 0.49 0.30–0.81 7.5 0.006
BNP (pg/ml) 1.0006 1.0004–1.0007 39 <0.0001 1.0003 1.0001–1.0006 8.6 0.003
LV ejection fraction (%) 0.97 0.94–0.99 4.2 0.04 1.01 0.98–1.05 0.6 0.44
Cachexia present 2.90 2.00–4.12 28 <0.0001 1.68 1.02–2.70 4.1 0.041
GFR (ml/min/1.73 m) 0.98 0.97–0.99 13 0.0004 0.99 0.97–1.01 2.5 0.11
Leg edema, present 1.62 1.14–2.29 7.0 0.008 1.17 0.48–0.76 0.5 0.48
Composite adverse outcome was deﬁned as death without transplantation, urgent transplantation, or implantation of ventricular assist device. Bold p values are < 0.05.
Abbreviations as in Tables 1 through 3.
Melenovsky et al. JACC Vol. 62, No. 18, 2013
RV Dysfunction and Cachexia in Advanced Heart Failure October 29, 2013:1660–70
1668cachexia noted in this study does not necessarily contradict
the important role of lean tissue wasting in the pathophys-
iology of advanced HF (29). During increased stress and
metabolic demand, fat can be preferentially mobilized and
lean tissue relatively spared. Fat loss may thus precede lean
mass depletion, as has been shown in cancer-related cachexia
(46,47). Increased adiposity may also lead to greater muscle
strength, which may facilitate some clinical beneﬁts (48). Fat
mass displayed a stronger correlation with prognosis than
fat-free mass, conﬁrming previous observations in a smaller,
less morbid HF cohort (6); however, in patients with stable
coronary disease, both higher fat and lean mass correlatedRight ventricular
dysfunction
natriuretic peptides
catecholamines
cortisol
venous congestion
anorexia
malabsorption
protein-losing enteropathy
gut bacteria translocation
inflammatory cytokines ?
TNF-α ?
lipotoxicity ?
Figure 5 RVD and Cardiac Cachexia
Possible bidirectional mechanisms linking RVD to cardiac cachexia in patients with
advanced heart failure. TNF ¼ tumor necrosis factor; other abbreviation as in
Figure 1.with a better prognosis (49,50). If fat loss is simply an
early surrogate of a pro-catabolic phase in HF preceding
loss of lean mass, or whether fat tissue provides some car-
dioprotective effects in HF, is currently unknown and
deserves further inquiry.
Study limitations. This prospective study was observational
and cross-sectional; therefore, causality cannot be addressed.
Due to potential referral bias, our cohort may not reﬂect
a general HF population. The deﬁnition of cachexia itself is
evolving (27), and we might have obtained slightly different
results if we had used a deﬁnition incorporating body
composition (10,16). Not accounting for ﬂuid loss secondary
to diuretics may confound our analysis, but most of the
patients had already been using diuretics for a long time, and
average right atrial pressures were not markedly elevated. In
addition, the presence of edema in the 6 months preceding
examination (29% of subjects) had no impact on outcome
(HR: 1.1; 95% CI: 0.7 to 1.5; p ¼ 0.8) in striking contrast to
reported weight loss, suggesting that the two are unrelated. If
patients with antecedent edema were excluded, cachexia
remained highly predictive of adverse outcome (HR: 3.5;
95% CI: 2.2 to 5.4; p < 0.0001).
Conclusions
This study showed that RVD and cardiac cachexia
frequently coexist, may be mechanistically linked, and
additively affect prognosis in patients with advanced HF.
Strategies improving RV function might prevent cardiac
cachexia, and, conversely, reversal of the wasting state may
allow for enhanced RV function. Wasting of fat mass, but
not of lean mass, was predictive of adverse outcome, sug-
gesting that fat mass loss is either a surrogate of enhanced
catabolism or adipose tissue confers some inherent car-
dioprotection in advanced HF.
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